Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL398854 | 1.00 | MAPT (0.48) | MAPTPOLBLMNAKDM4EHPGD | |
| SCHEMBL4697709 | 0.93 | MAPT (0.51) | MAPTPOLBLMNAKDM4EHPGD | |
| SCHEMBL4697713 | 0.93 | MAPT (0.51) | MAPTPOLBLMNAKDM4EHPGD | |
| SCHEMBL4697819 | 0.90 | MAPT (0.48) | MAPTPOLBLMNAKDM4EHPGD | |
| SCHEMBL4697823 | 0.90 | MAPT (0.48) | MAPTPOLBLMNAKDM4EHPGD | |
| SCHEMBL13673709 | 0.88 | MAPT (0.61) | MAPTLMNAKDM4EHPGDMEN1 | |
| SCHEMBL13673712 | 0.88 | MAPT (0.61) | MAPTLMNAKDM4EHPGDMEN1 | |
| SCHEMBL915547 | 0.86 | MAPT (0.40) | MAPTPOLBLMNAKDM4EHPGD | |
| SCHEMBL915549 | 0.86 | MAPT (0.40) | MAPTPOLBLMNAKDM4EHPGD | |
| SCHEMBL530029 | 0.85 | MAPT (0.55) | MAPTPOLBLMNAKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 328 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130295009-A1 | METHOD OF TREATING INFLAMMATION | HPF IP HOLDING S.A. (LU) | 2013-11-07 | — | — | US | claimed |
| WO-2008157537-A2 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC (US) | 2008-12-24 | — | — | WO | claimed |
| WO-2008124505-A2 | SOLUBLE GUANYLATE CYCLASE (SGC) MODULATORS FOR TREATMENT OF LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS,INC. (US) | 2008-10-16 | — | — | WO | claimed |
| US-20260116886-A1 | DEUTERATED sGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260000653-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-12435080-B2 | sGC stimulators | TISENTO THERAPEUTICS INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250115611-A1 | CRYSTALLINE FORMS OF 8-(2-FLUOROBENZYL)-6-(3-(TRIFLUOROMETHYL)-1H-1,2,4-TRIAZOL-5-YL)IMIDAZO[1,2-a]PYRAZINE AS sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2025-04-10 | — | — | US | disclosed |
| US-20250108040-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2025-04-03 | — | — | US | disclosed |
| US-20250059197-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2025-02-20 | — | — | US | disclosed |
| US-20240342187-A1 | USE OF NEP INHIBITORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DISORDERS | CURTAILS LLC (US) | 2024-10-17 | — | — | US | disclosed |
| US-20240228520-A9 | PHOSPHORUS PRODRUGS OF PYRAZOLO-SUBSTITUTED PYRIMIDINE SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2006055542-A2 | DIURETIC COMPOUNDS COMPRISING HETEROCYCLIC NITRIC OXIDE DONOR GROUPS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| WO-2006052899-A2 | NITROSATED AND NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPHTHALMIC DISORDERS | NITROMED, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| WO-2006041855-A2 | COMPOSITIONS AND METHODS USING APOCYNIN COMPOUNDS AND NITRIC OXIDE DONORS | NITROMED, INC. (US) | 2006-04-20 | — | — | WO | disclosed |
| WO-2005070006-A2 | NITROSATED AND/OR NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005023183-A2 | NITROSATED AD NITROSYLATED DIURETIC COMPOUDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| US-20050059655-A1 | Nitrosated and nitrosylated diuretic compounds, compositions and methods of use | NITROMED, INC. (US) | 2005-03-17 | — | — | US | disclosed |
| WO-2005023182-A2 | NITROSATED AND NITROSYLATED CARDIOVASCULAR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| WO-2005018561-A2 | NITROSATED AND NITROSYLATED CARDIOVASCULAR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20040024060-A1 | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands | ACURE PHARMA AB (SE) | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024060-A1 | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands | MC1R, MC5R, MCHR1 | MAPT 4496/4885POLB 3659/4885LMNA 4614/4885 |
| US-20250059197-A1 | sGC STIMULATORS | GMPS, GUCY1A2, PDE2A | MAPT 4676/4885POLB 3084/4885LMNA 3247/4885 |
| US-12435080-B2 | sGC stimulators | GUCY1A2, PRKG1, PDE2A | MAPT 4786/4885POLB 3118/4885LMNA 3153/4885 |
| US-20130295009-A1 | METHOD OF TREATING INFLAMMATION | MC2R, MC5R, MC1R | MAPT 3465/4885POLB 3116/4885LMNA 3918/4885 |
| US-20260116886-A1 | DEUTERATED sGC STIMULATORS | PDE2A, PRKG1, GUCY1A2 | MAPT 4558/4885POLB 4242/4885LMNA 2703/4885 |
| US-20260000653-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | PDE9A, PDE2A, GUCY1A2 | MAPT 1030/4885POLB 4306/4885LMNA 2031/4885 |
| US-20240228520-A9 | PHOSPHORUS PRODRUGS OF PYRAZOLO-SUBSTITUTED PYRIMIDINE SGC STIMULATORS | P2RY1, P2RY11, GMPS | MAPT 4822/4885POLB 2218/4885LMNA 4090/4885 |
| US-20050059655-A1 | Nitrosated and nitrosylated diuretic compounds, compositions and methods of use | REN, NOS1, NOS3 | MAPT 3126/4885POLB 4088/4885LMNA 615/4885 |
| US-20250115611-A1 | CRYSTALLINE FORMS OF 8-(2-FLUOROBENZYL)-6-(3-(TRIFLUOROMETHYL)-1H-1,2,4-TRIAZOL-5-YL)IMIDAZO[1,2-a]PYRAZINE AS sGC STIMULATORS | GUCY1A2, GUCY1B2, GUCY1A1 | MAPT 4385/4885POLB 3925/4885LMNA 1840/4885 |
| US-20250108040-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | GUCY1A2, GUCY1B2, PDE2A | MAPT 3160/4885POLB 4317/4885LMNA 4287/4885 |
| US-20240342187-A1 | USE OF NEP INHIBITORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DISORDERS | MME, REN, ACE | MAPT 711/4885POLB 1194/4885LMNA 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.